BS BSX Boston Scientific Loading... : Bullish and Bearish Analyst Opinions

The author advises against selling into deep losses and outlines a watchlist for potential tech, medical, and travel entries once downtrends stabilize, but expresses no current directional positions.

BSX trades at $44, down from $90 in January, with Value Line estimating EPS of $3.25 this year and $3.50 next year (P/E ~13.5x), and the company completed an $2B ASR at ~$53/share. The market overreacted to the Penumbra acquisition and debt concerns; if PEN shareholders take cash (as implied by the stock drop), BSX avoids dilution and can use strong cash flows to de-lever, while EPS continues to grow. Buying BSX at a 13-14x forward P/E with double-digit EPS growth and a management team that aggressively repurchases shares provides a margin of safety and upside potential over the medium to long term. Integration of Penumbra could underperform; debt load from the $14.5B acquisition may pressure margins or trigger downgrades; sector rotation away from medtech could keep the stock depressed.

Medical devices are in a deep funk.

BSX is a Fast Grower with a PEG ratio of 0.59 and trades 24% below the author’s calculated fair value. The Soros “Panic” signal indicates market sentiment is irrationally negative, creating a buying opportunity when fundamentals remain strong. Lynch’s cheap + Soros’ bearish sentiment combination historically precedes mean reversion; BSX offers a margin of safety with growth tailwinds. Medical device regulatory setbacks, slower revenue growth, or a broader healthcare downturn could invalidate the thesis.

BSX trades at ~$57 vs Morningstar fair value of $81 and CFRA $67.63; EPS CAGR estimated 11-16% over next 5 years; CEO Mahoney has driven 16% EPS growth since 2010 with 85% accuracy. Valuation gap (discount to fair value) combined with strong product moats (PFA, WATCHMAN) and a proven management turnaround creates a buying opportunity. BSX is undervalued relative to its historical and projected earnings power, with catalysts from new product cycles and a long-tenured CEO. Competition from JNJ and Medtronic eroding PFA market share (projected drop from 58% to 48% by 2026); execution hiccups and recent guidance down; sector becoming capex-heavy and binary.

SEC FOIA logs reveal ongoing investigations for listed companies, indicating regulatory scrutiny but no directional view expressed.

Bearish view on BSX expecting stock decline on CEO retirement catalyst in ~2 years; recent overearning will revert, and sour investor sentiment compounds downside.

Bearish view on BSX as CEO's $15M insider sale before a blackout period signals bearish conviction about the company's near-term outlook.

The tweet implies insider selling by BSX's CEO before a blackout period, suggesting bearish sentiment on the stock's near-term outlook.

Bearish view on BSX as the sharp +9% squeeze is unsustainable and signals a negative reversal.

Boston Scientific wait for bottom

Boston Scientific's CHAMPION trial results are viewed as meeting guidelines but failing to provide the significant upside bulls expected.

The author is bullish on Boston Scientific due to strong long-term earnings potential and high trial success probability, despite some short-term concerns regarding Q1 performance.